Indications for use of Arbidol are:

- treatment and prevention of influenza and other acute respiratory infections (including those complicated by bronchitis and pneumonia);

- as part of the combined therapy of chronic bronchitis, pneumonia and recurrent herpes infection;

- as part of the complex therapy of acute intestinal infections of rotavirus etiology in children over 2 years old;

- prevention of postoperative infectious complications;

- normalization of the immune status.

Pharmacological properties:

 Pharmacodynamics:

Antiviral agent. Specifically suppresses in vitro influenza A and B viruses (Influenzavirus A, B), including highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses - causative agents of acute respiratory viral infections (ARVI) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)).

According to the mechanism of antiviral action, it belongs to fusion inhibitors (fusion), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes.

It has a moderate immunomodulatory effect, increases the body's resistance to viral infections. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted already after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration.

Stimulates cellular and humoral reactions of immunity: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells).

Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with a viral infection and exacerbations of chronic bacterial diseases.

In the treatment of influenza or acute respiratory viral infections in adult patients, a clinical study showed that the effect of Arbidol® in adult patients is most pronounced in the acute period of the disease and manifests itself in a reduction in the resolution of the symptoms of the disease, a decrease in the severity of the manifestations of the disease and a reduction in the time for elimination of the virus.

Therapy with Arbidol® leads to a higher frequency of relief of symptoms of the disease on the third day of therapy compared with placebo. 60 hours after the start of therapy, resolution of all symptoms of laboratory-confirmed influenza was more than 5 times higher than in the placebo group.

A significant effect of the drug Arbidol® on the rate of elimination of the influenza virus was established, which, in particular, was manifested by a decrease in the frequency of detection of the RNA virus on the 4th day.

Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.

Pharmacokinetics:

It is quickly absorbed and distributed to organs and tissues. The maximum concentration in blood plasma is reached after 1.5 hours. It is metabolized in the liver. The half-life is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount by the kidneys (0.12%). During the first day, 90% of the administered dose is removed.